SCHEMBL25456788

SCHEMBL25456788

COc1ccc(CN(CCOP(=O)(O)O)C(=O)CCCCc2cccc(CCCCCc3ccc(-c4ccccc4)cc3)c2)cc1

nearest known ligand 0.48

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ALOX5 P09917 2/20 0.48
▸ LPAR1 Q92633 11/20 0.47
▸ FAAH O00519 1/20 0.44
▸ RAF1 P04049 2/20 0.43
▸ MAP2K1 Q02750 2/20 0.43
▸ LPAR5 Q9H1C0 2/20 0.43
▸ S1PR4 O95977 1/20 0.42
▸ S1PR1 P21453 1/20 0.42
▸ S1PR3 Q99500 1/20 0.42
▸ S1PR5 Q9H228 1/20 0.42
▸ LTB4R2 Q9NPC1 1/20 0.42
▸ BCHE P06276 1/20 0.41
▸ ACHE P22303 1/20 0.41
▸ LPAR3 Q9UBY5 1/20 0.41
▸ HSD17B2 P37059 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25456779 0.92 SLC2A1 (0.51) ALOX5LPAR1RAF1MAP2K1S1PR4
Ammonia Solution, Strong SCHEMBL25173211 0.92 SLC2A1 (0.47) ALOX5LPAR1FAAHRAF1MAP2K1
Ammonia Solution, Strong SCHEMBL25169871 0.92 SLC2A1 (0.51) ALOX5LPAR1RAF1MAP2K1S1PR4
SCHEMBL25456789 0.91 S1PR1 (0.51) ALOX5LPAR1FAAHS1PR4S1PR1
SCHEMBL25456787 0.90 S1PR1 (0.49) ALOX5LPAR1FAAHS1PR4S1PR1
Ammonia Solution, Strong SCHEMBL25167618 0.90 S1PR1 (0.51) ALOX5LPAR1FAAHS1PR4S1PR1
Ammonia Solution, Strong SCHEMBL25169992 0.89 S1PR1 (0.48) ALOX5LPAR1FAAHS1PR4S1PR1
SCHEMBL25456761 0.89 SLC2A1 (0.51) ALOX5LPAR1RAF1MAP2K1LPAR5
SCHEMBL25456753 0.89 ALOX5 (0.52) ALOX5LPAR1RAF1MAP2K1LPAR5
Ammonia Solution, Strong SCHEMBL25172939 0.88 ALOX5 (0.51) ALOX5LPAR1RAF1MAP2K1LPAR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11802135-B2 Lysophosphatidic acid derivative MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-10-31 — — US disclosed
US-11802135-B2 Lysophosphatidic acid derivative MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-10-31 — — US disclosed
US-20230146210-A1 NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-05-11 — — US disclosed
US-20230146210-A1 NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-05-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11802135-B2 Lysophosphatidic acid derivative LPAR4, LPAR2, LPAR1 ALOX5 134/4885LPAR1 3/4885FAAH 304/4885
US-20230146210-A1 NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE LPAR4, LPAR2, LPAR1 ALOX5 165/4885LPAR1 3/4885FAAH 320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback